The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Patna has witnessed a major breakthrough in the field of pain management and orthopaedic care as renowned pain specialist Dr.

Professional organizations such as the American College of Rheumatology and the American Academy of Orthopaedic Surgeons strongly recommend exercise and other conservative modalities of care prior to ...

The event also highlights the importance of non-opioid therapies for managing both acute and chronic pain. Pacira BioSciences ...

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering ...

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Cipla and Stempeutics launch Ciplostem, a DCGI-approved cell therapy for Grade II–III Knee Osteoarthritis, offering long-term ...

U.S. Army Sergeant Stormy Fuller Smith, diagnosed with cancer at 20, reunites with a puppy he rescued overseas, thanks to ...